These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32538461)

  • 1. Risk of infections in psoriasis. A lesson to learn during the SARS-CoV-2 pandemic.
    Naldi L
    Br J Dermatol; 2021 Jan; 184(1):6. PubMed ID: 32538461
    [No Abstract]   [Full Text] [Related]  

  • 2. Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic.
    Cazzaniga S; Naldi L
    Br J Dermatol; 2022 Jan; 186(1):7-8. PubMed ID: 34726776
    [No Abstract]   [Full Text] [Related]  

  • 3. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France.
    Penso L; Dray-Spira R; Weill A; Zureik M; Sbidian E
    Br J Dermatol; 2022 Jan; 186(1):59-68. PubMed ID: 34310699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [BIOLOGICAL TREATMENT OF PSORIASIS IN TIME OF NEW CORONAVIRUS INFECTION COVID-19].
    Kruglova LS; Pereverzina NO; Rudneva NS; Kamynina NN; Oynotkinova OS
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Aug; 29(Special Issue):1381-1387. PubMed ID: 34792893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for treatment of nail psoriasis during the COVID-19 pandemic.
    Ricardo JW; Lipner SR
    Dermatol Ther; 2020 Jul; 33(4):e13757. PubMed ID: 32495952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
    Gisondi P; Facheris P; Dapavo P; Piaserico S; Conti A; Naldi L; Cazzaniga S; Malagoli P; Costanzo A
    Br J Dermatol; 2020 Aug; 183(2):373-374. PubMed ID: 32343839
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of COVID-19 pandemic on psoriasis patients in northern Greece.
    Apalla Z; Fotiadou C; Emvalomati A; Patsatsi A; Trakatelli M; Trigoni A; Kyrgidis A; Trakatelli C; Papazisis G; Lallas A; Droggoula O; Giannakaki MM; Oflidou V; Siskou S; Boziou M; Karydi K; Daponte A; Kemanetzi C; Tsatsou F; Kyrmanidou E; Lazaridou E
    Dermatol Ther; 2022 Feb; 35(2):e15244. PubMed ID: 34862701
    [No Abstract]   [Full Text] [Related]  

  • 8. Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic.
    Penso L; Dray-Spira R; Weill A; Zureik M; Sbidian E
    Br J Dermatol; 2021 Sep; 185(3):671-673. PubMed ID: 33894022
    [No Abstract]   [Full Text] [Related]  

  • 9. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study.
    Mahil SK; Yates M; Yiu ZZN; Langan SM; Tsakok T; Dand N; Mason KJ; McAteer H; Meynell F; Coker B; Vincent A; Urmston D; Vesty A; Kelly J; Lancelot C; Moorhead L; Bachelez H; Capon F; Contreras CR; De La Cruz C; Di Meglio P; Gisondi P; Jullien D; Lambert J; Naldi L; Norton S; Puig L; Spuls P; Torres T; Warren RB; Waweru H; Weinman J; Brown MA; Galloway JB; Griffiths CM; Barker JN; Smith CH;
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e636-e640. PubMed ID: 34145643
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical management of psoriasis patients during the COVID-19 pandemic.
    Chat VS; Uppal SK; Kearns DG; Wu JJ
    J Dermatolog Treat; 2022 Mar; 33(2):1166-1167. PubMed ID: 32568009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?
    Rosi E; Pimpinelli N; Prignano F
    J Dermatolog Treat; 2022 Feb; 33(1):599. PubMed ID: 32432955
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply: "Biologics for psoriasis during COVID-19 outbreak".
    Di Lernia V
    J Am Acad Dermatol; 2020 Jun; 82(6):e217-e218. PubMed ID: 32283234
    [No Abstract]   [Full Text] [Related]  

  • 13. Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation.
    Gondo GC; Bell SJ; Slayden J; Ullmann G; Blauvelt A
    J Eur Acad Dermatol Venereol; 2021 Jun; 35(6):e354-e355. PubMed ID: 33587770
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study.
    Kridin K; Schonmann Y; Damiani G; Peretz A; Onn E; Bitan DT; Cohen AD
    Dermatol Ther; 2021 Jul; 34(4):e15003. PubMed ID: 34033207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs.
    Mroz M; Mućka S; Miodońska M; Ziolkowska D; Hadas E; Bożek A
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577804
    [No Abstract]   [Full Text] [Related]  

  • 16. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.
    Talamonti M; Galluzzo M; Chiricozzi A; Quaglino P; Fabbrocini G; Gisondi P; Marzano AV; Potenza C; Conti A; Parodi A; Piaserico S; Bardazzi F; Argenziano G; Rongioletti F; Stingeni L; Micali G; Loconsole F; Rossi MT; Bongiorno MR; Feliciani C; Rubegni P; Amerio P; Fargnoli MC; Pigatto P; Savoia P; Nisticò SP; Giustini S; Carugno A; Cannavo' SP; Rech G; Prignano F; Offidani A; Lombardo M; Zalaudek I; Bianchi L; Peris K; ; Balestri R ; Bernardini N ; Belloni Fortini A ; Burlando M ; Caldarola G ; Campione E ; Cattaneo A ; Dapavo P ; Dastoli S ; De Simone C ; Di Nuzzo S ; Diotallevi F ; Fierro MT ; Franchi C ; Esposito M ; Foti C ; Gambini DM ; Gambardella A ; Girolomoni G ; Giunta A ; Guarneri C ; Gualdi G ; Hansel K ; Megna M ; Mugheddu C ; Musumeci ML ; Patrizi A ; Pellacani G ; Richetta AG ; Rosi E ; Sacchelli L ; Tiberio R ; Tilotta G ; Trovato E ; Venturini M ; Vezzoni R
    Expert Opin Biol Ther; 2021 Feb; 21(2):271-277. PubMed ID: 33216643
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of infections in psoriasis: assessment and challenges in daily management.
    De Simone C; Fargnoli MC; Amerio P; Bianchi L; Esposito M; Pirro F; Potenza C; Ricceri F; Rongioletti F; Stingeni L; Prignano F
    Expert Rev Clin Immunol; 2021 Nov; 17(11):1211-1220. PubMed ID: 34696673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul.
    Kara Polat A; Oguz Topal I; Karadag AS; Aksoy H; Koku Aksu AE; Ozkur E; Ozkok Akbulut T; Topaloglu Demir F; Engin B; Uzuncakmak TK; Kıvanc Altunay I
    Dermatol Ther; 2021 Jan; 34(1):e14691. PubMed ID: 33351215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits.
    Conforti C; Giuffrida R; Dianzani C; Di Meo N; Zalaudek I
    Dermatol Ther; 2020 Jul; 33(4):e13490. PubMed ID: 32358864
    [No Abstract]   [Full Text] [Related]  

  • 20. Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
    Polat Ekinci A; Pehlivan G; Gökalp MO
    Dermatol Ther; 2021 Jan; 34(1):e14700. PubMed ID: 33369063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.